Small Study Suggests Possible Benefit for Skin Patch to Reduce Immune Activity in Multiple Sclerosis - National Multiple Sclerosis Society

Skip to navigation Skip to content

News

Share

Small Study Suggests Possible Benefit for Skin Patch to Reduce Immune Activity in Multiple Sclerosis

July 9, 2013

Polish researchers reported results of a small clinical trial in which a skin patch containing myelin peptides (portions of the substance that insulates nerve fibers and is a target of the immune attack on the brain and spinal cord in MS) were administered to 20 people with relapsing-remitting MS via a skin patch, resulting in significant reductions in disease activity on imaging scans and relapses, compared with 10 people given an inactive placebo patch. Over one year, the treatment was found to be safe and well tolerated. Further studies in larger numbers of people are necessary to determine whether this method has potential as a safe and effective treatment approach for people with MS. Agata Walczak, MD, PhD, and Krzysztof Selmaj, MD, PhD (University of Lodz, Poland) and colleagues report their findings in JAMA Neurology (Published online July 1, 2013).

Background: In MS, immune cells called T cells attack and destroy myelin, the substance that protects nerve fibers, and cause other damage in the brain and spinal cord. These attacks lead to clinical symptoms. In people who don’t have MS, these T cells do not attack myelin because it is recognized as part of their own body, and their immune systems are trained to be “tolerant” to myelin and so do not attack it. One goal in MS therapy is to selectively restore normal tolerance to one’s own myelin, leaving the rest of the immune system intact.  In previous studies, researchers have administered a myelin protein (myelin basic protein) orally to mice with EAE, an MS-like disease, and succeeded in suppressing disease, but a clinical trial of this approach involving people with MS was not successful.

The skin is the first line of immune defense, and contains large numbers of immune cells. Applying myelin peptides to the skin of mice with an MS-like disease resulted in suppression of disease (Journal of Autoimmunity, 2007;28:208). The current study tested this approach in a small study in people with relapsing-remitting MS.

The study: Investigators enrolled thirty participants with relapsing-remitting MS, and randomly assigned 16 to receive a 1-mg patch containing a mixture of three myelin peptides (myelin basic protein, proteolipid protein, and myelin oligodendrocyte protein), four to receive a 10-mg myelin peptide patch, and 10 to receive an inactive placebo patch. The adhesive skin patch was placed on the right upper arm and was changed once a week for 4 weeks and then once a month for 11 months. MRI scans were performed at the start of the study and every three months until the end of the study.

The primary outcome measured was whether treatment reduced new disease activity seen on MRI scans significantly more than placebo, and secondary outcomes measured included other MRI findings, annual relapse rate, the proportion of relapse-free patients, and the proportion of patients who experienced 3 months of confirmed disability worsening, as measured by the EDSS disability scale.

The investigators reported that for those on the 1-mg patch, disease activity on MRI scans was reduced significantly, a reduction that was detected at three months of treatment. The annual relapse rate was reduced by 69.3% versus placebo. The proportion of relapse-free patients was 63% of the 1-mg group, versus 10% of those on placebo. The proportion of those with worsening disability decreased by 51%. The 10-mg dose was less effective. No serious adverse events occurred. A mild local skin reaction was observed in some people receiving the myelin peptide patch but resolved without treatment. Laboratory test results also did not show any blood, liver or kidney abnormalities.

Comments: This study used a novel and intriguing attempt to induce the immune system to stop attacking the nervous system in people with relapsing MS. Further studies in larger numbers of people are necessary to determine whether this method has potential as a safe and effective treatment approach for people with MS.

Read more about novel immune system research in MS.

Read more about efforts to stop MS in its tracks.

About Multiple Sclerosis

Multiple sclerosis, an unpredictable, often disabling disease of the central nervous system, interrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 2.3 million people worldwide.

Share